SleepWell Trade

Trend-Following Backtester · Guide · backtest 한국어

equity · US

C4 Therapeutics, Inc. backtest

10 trend-following strategies were compared on the full daily history of C4 Therapeutics, Inc.. 10 beat buy-and-hold CAGR; ADX / DI 방향성 ranks first by Sharpe, matching the main backtester. The return/drawdown alternative is 볼린저 밴드 돌파 (CAGR 19.6%, MDD -48.5%).

Data 2020-10-02 ~ 2026-07-31daily bars 1,463 (5.8 years)Costs 0.5%Venue XNASMonthly snapshot 2026-07-31

Results by strategy

10 of 10 beat buy and hold (CAGR -29.0%, drawdown -97.8%).

Sharpe leader (same as main): ADX / DI 방향성 — CAGR 22.0%, MDD -64.0%, Sharpe 0.54, 29% exposure.

Return/drawdown alternative: 볼린저 밴드 돌파 — CAGR is 51.0%p higher than buy and hold, while drawdown improves by 33.8%p (CAGR 19.6%, MDD -48.5%, exposure 27%).

The alternative must retain 75% of buy-and-hold CAGR, improve drawdown by at least 20% and 5 percentage points, and stay below 95% exposure; the ranking weights return retention 60% and drawdown improvement 40%.

Strategy · parametersCAGRMDDSharpeCalmarTotalTradesExposure
ADX / DI 방향성
period=59, threshold=11
22.0%-64.0%0.540.343.2x729%
볼린저 밴드 돌파
n=42, k=1.9
19.6%-48.5%0.510.402.8x2827%
Supertrend
period=7, mult=3.1
14.7%-70.2%0.490.212.2x3248%
Keltner 채널 돌파
emaPeriod=45, atrPeriod=25, mult=2.4
16.8%-49.3%0.470.342.5x1821%
ROC 모멘텀
n=38, threshold=0.03
9.8%-70.5%0.420.141.7x8641%
Parabolic SAR
step=0.055, maxStep=0.1
8.9%-79.6%0.420.111.6x14243%
Donchian 채널 돌파
entryN=13, exitN=41
-5.5%-88.6%0.31-0.060.7x2457%
SMA 크로스오버
fast=55, slow=62
1.5%-63.9%0.290.021.1x3343%
EMA 크로스오버
fast=20, slow=48
-3.7%-68.0%0.19-0.050.8x2341%
MACD
fast=12, slow=39, signal=6
-18.5%-81.0%0.10-0.230.3x11651%
Buy and hold-29.0%-97.8%0.17-0.300.1x1100%
0.1 1x 2021 2022 2023 2024 2025 2026 ADX / DI 방향성Buy and hold
ADX / DI 방향성: Solid strategy line versus dashed buy-and-hold line. Log scale.
0% -24% -49% -73% -98% 2021 2022 2023 2024 2025 2026 Buy and holdADX / DI 방향성
ADX / DI 방향성 maximum drawdown -64.0% (2024-03-08 → 2026-02-05), prior peak not yet recovered.

Rules of the top strategy

Looks at both the direction and the strength of the trend; holds only in a strong uptrend.

Method and caveats

Past performance does not guarantee future returns. Parameters were selected on the same full-history sample using sharpe over 40 trials per strategy, so results contain in-sample bias. 0.5% trading costs are included; taxes, slippage and rejected orders are not.
Re-run the same setupMore US assetsAll asset reports

Read next